Gastric mucosal ablation electrode MOVIVA®

endoscopicgastricplasma

Overview
MOVIVA® is an innovative, minimally invasive endoscopic solution for gastric mucosal ablation (GMA) in the fundus. It reduces the patient’s hunger feeling and, when combined with Endoscopic Sleeve Gastroplasty (ESG), GMA can yield weight loss results comparable to traditional bariatric surgery.

Key concept — GMA: How it works
The GMA procedure involves ablating the mucosa of the gastric fundus. This reduces the production of ghrelin (the hunger hormone), resulting in less hunger and fewer cravings. Ablation also leads to shrinkage of the fundus, reducing stomach capacity.

GMA procedure with MOVIVA®
First the distal fundal border is marked with dots using short activations of APC. The area to be ablated is elevated with saline solution by means of high-pressure needle-free injection and then ablated with argon plasma coagulation (APC). These two steps are repeated until the entire area has been ablated. When GMA is combined with ESG, the approach achieves weight loss outcomes comparable to vertical sleeve gastrectomy (VSG), while being less invasive.

Product technology — MOVIVA® hybrid instrument
MOVIVA® is an advanced hybrid instrument designed for GMA. It combines two key functions in one product:

• Injection of fluid to form a submucosal cushion that protects deeper tissue layers from thermal injury (high-pressure, needle-free injection).
• Superficial thermal ablation of the mucosa using argon plasma coagulation (APC). MOVIVA® is equipped with the dedicated moveAPD® mode, delivering broad and consistent APC.

Clinical context & benefits

• Targets appetite regulation by reducing ghrelin production and reducing fundus size.
• Enables less invasive treatment options for patients who wish to avoid surgical bariatric procedures.
• When combined with ESG, early clinical data show total body weight loss outcomes comparable to surgical sleeve gastrectomy in initial trials.

Training & support
Dedicated training courses are offered to support reliable results during GMA with MOVIVA®. Training is available in various countries and regions.

Selected clinical evidence & publications

• Gadi SR, et al. (2026) — Pilot clinical trial: Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity. Conclusion: Sequential GFMA followed by ESG is safe, feasible and highly effective, resulting in substantial and clinically meaningful weight loss; larger and long-term studies required for validation.
• Boškoski Ivo et al. (2026) — Case report: Combined gastric mucosal ablation of the fundus using a new hybrid device with ESG. Conclusion: Combined approach is feasible and safe with promising short-term weight loss outcomes; larger studies needed.
• McGowan C. E., et al. (2025) — Results from two first-in-human studies combining gastric fundus mucosal ablation and ESG. Conclusion: Integration of GFMA with ESG offers a promising, minimally invasive alternative to surgical weight loss procedures with favorable safety profile.
• De Siena et al. (2025) — Pilot study: Efficacy and safety of GMA of the fundus with HybridAPC combined with ESG.
• Maselli, D. B., et al. (2024) — Endoscopic gastric fundal mucosal ablation induces weight loss in adults with obesity.

Expert comments / Testimonials

• Prof. Ivo Boskoski, Rome, Italy: “Minimally invasive endoscopic techniques that target appetite regulation through precise ablation of the gastric fundus offer patients an effective pathway to weight loss without the risks associated with surgery. MOVIVA®’s innovative injection and ablation capabilities simplify the GMA procedure and could set a new standard in endoscopic bariatric care.”
• Christopher McGowan, MD, Charlotte, U.S.: “Combining GMA with ESG represents one of the most promising breakthroughs in non-surgical weight loss treatment. In our early clinical trials, this dual approach achieved total body weight loss of 23 to 24 percent - comparable to surgical sleeve gastrectomy, but without the need for surgery. Patients consistently report greater control over hunger, reduced cravings, and an improved relationship with food.”

Additional resources
An electronic promotional e‑flyer and press materials are available for download from the product page (PDF resources and press releases).

Caractéristiques / spécifications techniques

• Function: Hybrid system combining high-pressure needle-free saline injection and argon plasma coagulation (APC).
• Injection: Submucosal cushion formation via needle-free high-pressure injection.
• Ablation: Superficial mucosal ablation using APC with moveAPD® mode for broad, consistent coagulation.
• Intended procedure: Gastric mucosal ablation (GMA) of the fundus; can be combined with Endoscopic Sleeve Gastroplasty (ESG).
• Clinical effect: Reduces ghrelin production and fundus volume; aims to decrease hunger and stomach capacity.
• Use setting: Endoscopic, minimally invasive outpatient procedure.
• Training: Dedicated procedural training courses provided.